Blueprint Medicines Corporation
BPMC
Rangering i aksjer
#2354
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Aksjekurs
$129.46
Sist synkronisert: 2025-07-18
Markedsverdi
$8.36B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Blueprint Medicines Corporation (BPMC)
Kategori
Healthcare
Driftsmargin for Blueprint Medicines Corporation (BPMC)
Driftsmargin per October 2026 TTM: -41.67%
Ifølge Blueprint Medicines Corporation sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) -41.67%. Ved slutten av 2023 hadde selskapet en driftsmargin på -194.99%.
Historikk for driftsmargin for Blueprint Medicines Corporation fra 2013 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | -41.67% | 0.00% |
| 2024 | -41.67% | -78.63% |
| 2023 | -194.99% | -27.56% |
| 2022 | -269.19% | -25.25% |
| 2021 | -360.10% | -1,045.89% |
| 2020 | 38.07% | -106.91% |
| 2019 | -551.16% | -0.67% |
| 2018 | -554.86% | -20.47% |
| 2017 | -697.64% | 163.22% |
| 2016 | -265.04% | -43.01% |
| 2015 | -465.10% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -100.93% |
US
|
|
| -149.01% | -96.42% |
US
|
|
| 25.57% | -100.61% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.69% |
NL
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.